AstraZeneca, Ionis heart drug fails in Phase 3

AstraZeneca and Ionis' investigational cardiovascular drug, an antisense oligonucleotide, failed to meet its primary endpoint in a Phase 3 trial. The drug aimed to reduce the risk of major adverse cardiovascular events in patients with high triglycerides and established cardiovascular disease. The unexpected failure has implications for similar RNA-based therapies in development.